全文获取类型
收费全文 | 15245篇 |
免费 | 1215篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 336篇 |
儿科学 | 471篇 |
妇产科学 | 312篇 |
基础医学 | 2058篇 |
口腔科学 | 299篇 |
临床医学 | 1547篇 |
内科学 | 2785篇 |
皮肤病学 | 116篇 |
神经病学 | 1738篇 |
特种医学 | 659篇 |
外科学 | 2542篇 |
综合类 | 210篇 |
一般理论 | 10篇 |
预防医学 | 1281篇 |
眼科学 | 473篇 |
药学 | 906篇 |
中国医学 | 11篇 |
肿瘤学 | 756篇 |
出版年
2021年 | 325篇 |
2020年 | 197篇 |
2019年 | 307篇 |
2018年 | 387篇 |
2017年 | 306篇 |
2016年 | 285篇 |
2015年 | 319篇 |
2014年 | 481篇 |
2013年 | 679篇 |
2012年 | 1014篇 |
2011年 | 981篇 |
2010年 | 604篇 |
2009年 | 469篇 |
2008年 | 826篇 |
2007年 | 883篇 |
2006年 | 920篇 |
2005年 | 870篇 |
2004年 | 722篇 |
2003年 | 773篇 |
2002年 | 703篇 |
2001年 | 289篇 |
2000年 | 256篇 |
1999年 | 269篇 |
1998年 | 174篇 |
1997年 | 115篇 |
1996年 | 140篇 |
1995年 | 102篇 |
1994年 | 102篇 |
1993年 | 100篇 |
1992年 | 190篇 |
1991年 | 197篇 |
1990年 | 190篇 |
1989年 | 162篇 |
1988年 | 145篇 |
1987年 | 172篇 |
1986年 | 136篇 |
1985年 | 149篇 |
1984年 | 122篇 |
1983年 | 112篇 |
1982年 | 86篇 |
1981年 | 85篇 |
1980年 | 81篇 |
1979年 | 90篇 |
1978年 | 91篇 |
1977年 | 73篇 |
1976年 | 74篇 |
1975年 | 62篇 |
1974年 | 80篇 |
1973年 | 64篇 |
1972年 | 66篇 |
排序方式: 共有10000条查询结果,搜索用时 20 毫秒
991.
M Begoña Cachón-González Susan Z Wang Rosamund McNair Josephine Bradley David Lunn Robin Ziegler Seng H Cheng Timothy M Cox 《Molecular therapy》2012,20(8):1489-1500
The GM2 gangliosidoses are fatal lysosomal storage diseases principally affecting the brain. Absence of β-hexosaminidase A and B activities in the Sandhoff mouse causes neurological dysfunction and recapitulates the acute Tay–Sachs (TSD) and Sandhoff diseases (SD) in infants. Intracranial coinjection of recombinant adeno-associated viral vectors (rAAV), serotype 2/1, expressing human β-hexosaminidase α (HEXA) and β (HEXB) subunits into 1-month-old Sandhoff mice gave unprecedented survival to 2 years and prevented disease throughout the brain and spinal cord. Classical manifestations of disease, including spasticity—as opposed to tremor-ataxia—were resolved by localized gene transfer to the striatum or cerebellum, respectively. Abundant biosynthesis of β-hexosaminidase isozymes and their global distribution via axonal, perivascular, and cerebrospinal fluid (CSF) spaces, as well as diffusion, account for the sustained phenotypic rescue—long-term protein expression by transduced brain parenchyma, choroid plexus epithelium, and dorsal root ganglia neurons supplies the corrective enzyme. Prolonged survival permitted expression of cryptic disease in organs not accessed by intracranial vector delivery. We contend that infusion of rAAV into CSF space and intraparenchymal administration by convection-enhanced delivery at a few strategic sites will optimally treat neurodegeneration in many diseases affecting the nervous system. 相似文献
992.
Cho WS Duffin R Poland CA Duschl A Oostingh GJ Macnee W Bradley M Megson IL Donaldson K 《Nanotoxicology》2012,6(1):22-35
993.
994.
995.
Shi JQ Lasky K Shinde V Stringer B Qian MG Liao D Liu R Driscoll D Nestor MT Amidon BS Rao Y Duffey MO Manfredi MG Vos TJ Amore ND Hyer ML 《Molecular cancer therapeutics》2012,11(9):2045-2053
Diffuse large B-cell lymphoma (DLBCL) is the most common of the non-Hodgkin lymphomas, accounting for up to 30% of all newly diagnosed lymphoma cases. Current treatment options for this disease are effective, but not always curative; therefore, experimental therapies continue to be investigated. We have discovered an experimental, potent, and selective small-molecule inhibitor of PLK1, MLN0905, which inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lines. In our report, we explored the pharmacokinetic, pharmacodynamic, and antitumor properties of MLN0905 in DLBCL xenograft models grown in mice. These studies indicate that MLN0905 modulates the pharmacodynamic biomarker phosphorylated histone H3 (pHisH3) in tumor tissue. The antitumor activity of MLN0905 was evaluated in three human subcutaneous DLBCL xenograft models, OCI LY-10, OCI LY-19, and PHTX-22L (primary lymphoma). In each model, MLN0905 yielded significant antitumor activity on both a continuous (daily) and intermittent dosing schedule, underscoring dosing flexibility. The antitumor activity of MLN0905 was also evaluated in a disseminated xenograft (OCI LY-19) model to better mimic human DLBCL disease. In the disseminated model, MLN0905 induced a highly significant survival advantage. Finally, MLN0905 was combined with a standard-of-care agent, rituximab, in the disseminated OCI LY-19 xenograft model. Combining rituximab and MLN0905 provided both a synergistic antitumor effect and a synergistic survival advantage. Our findings indicate that PLK1 inhibition leads to pharmacodynamic pHisH3 modulation and significant antitumor activity in multiple DLBCL models. These data strongly suggest evaluating PLK1 inhibitors as DLBCL anticancer agents in the clinic. Mol Cancer Ther; 11(9); 2045-53. ?2012 AACR. 相似文献
996.
997.
998.
999.
1000.
Zyblewski SC Argraves WS Graham EM Slate EH Atz AM Bradley SM McQuinn TC Wilkerson BA Wing SB Argraves KM 《Pediatric cardiology》2012,33(7):1154-1159
Despite the emerging relevance of high-density lipoprotein (HDL) in the inflammatory cascade and vascular barrier integrity, HDL levels in children undergoing cardiac surgery are unexplored. As a measure of HDL levels, the HDL-cholesterol (HDL-C) in single-ventricle patients was quantified before and after the Fontan operation, and it was determined whether relationships existed between the duration and the type of postoperative pleural effusions. The study prospectively enrolled 12 children undergoing the Fontan operation. Plasma HDL-C levels were measured before and after cardiopulmonary bypass. The outcome variables of interest were the duration and type of chest tube drainage (chylous vs. nonchylous). The Kendall rank correlation coefficient and the Wilcoxon rank sum test were used. There were 11 complete observations. The median preoperative HDL-C level for all the subjects was 30?mg/dl (range, 24-53?mg/dl), and the median postcardiopulmonary bypass level was 21?mg/dl (range, 14-46?mg/dl) (p?=?0.004). There was a tendency toward a moderate inverse correlation (-0.42) between the postcardiopulmonary bypass HDL-C level and the duration of chest tube drainage, but the result was not statistically significant (p?=?0.07). In the chylous effusion group, the median postcardiopulmonary bypass HDL-C tended to be lower (16 vs. 23?mg/dl; p?=?0.09). After the Fontan operation, the plasma HDL-C levels in children are significantly reduced. It is reasonable to conclude that the reduction in HDL-C reflects reduced plasma levels of HDL particles, which may have pertinent implications in postoperative pleural effusions given the antiinflammatory and endothelial barrier functions of HDL. 相似文献